Citigroup lifted its price objective and gave a buy rating for Beam Therapeutics, while Bank of America restated its buy rating and set a new price target.
4 reports, 1 independent
Updated Sep 9
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup lifted its price objective and gave a buy rating for Beam Therapeutics, while Bank of America restated its buy rating and set a new price target.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Beam Therapeutics
American healthcare company
Nothing else this week.
-
Citigroup
American investment bank and financial services corporation
-
Bank of America
American multinational banking and financial services corporation
Related events
- Citigroup and Royal Bank of Canada raised price targets and ratings for a company, with MarketBeat aggregating the financial data.
- MarketBeat published average ratings and price targets for Kalaris Therapeutics, while Citigroup reaffirmed an outperform rating and TD Cowen initiated coverage with a buy rating.
- Bank of America lifted its price objective and issued a 'buy' rating for BridgeBio Pharma, concurrent with a required institutional investment filing.
- Citigroup and Truist Financial issued buy ratings and increased price targets for Cisco.
- Citigroup lifted its target price and gave a buy rating for BLOCK, while K&B&W upped its price objective and gave an outperform rating.